These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24276029)

  • 1. A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive Italian women.
    Cortesi L; Razzaboni E; Toss A; De Matteis E; Marchi I; Medici V; Tazzioli G; Andreotti A; De Santis G; Pignatti M; Federico M
    Ann Oncol; 2014 Jan; 25(1):57-63. PubMed ID: 24276029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients.
    Schwartz MD; Peshkin BN; Isaacs C; Willey S; Valdimarsdottir HB; Nusbaum R; Hooker G; O'Neill S; Jandorf L; Kelly SP; Heinzmann J; Zidell A; Khoury K
    Breast Cancer Res Treat; 2018 Aug; 170(3):517-524. PubMed ID: 29611029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast reconstruction after risk-reducing mastectomy in BRCA mutation carriers.
    Nagura N; Hayashi N; Takei J; Yoshida A; Ochi T; Iwahira Y; Yamauchi H
    Breast Cancer; 2020 Jan; 27(1):70-76. PubMed ID: 31292927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
    Donenberg T; George S; Ali J; Bravo G; Hernandez K; Sookar N; Ashing KT; Narod SA; Akbari MR; Hurley J
    Breast Cancer Res Treat; 2019 Apr; 174(2):469-477. PubMed ID: 30515680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of rapid genetic counselling and testing on the decision to undergo immediate or delayed prophylactic mastectomy in newly diagnosed breast cancer patients: findings from a randomised controlled trial.
    Wevers MR; Aaronson NK; Verhoef S; Bleiker EM; Hahn DE; Kuenen MA; van der Sanden-Melis J; Brouwer T; Hogervorst FB; van der Luijt RB; Valdimarsdottir HB; van Dalen T; Theunissen EB; van Ooijen B; de Roos MA; Borgstein PJ; Vrouenraets BC; Vriens E; Bouma WH; Rijna H; Vente JP; Witkamp AJ; Rutgers EJ; Ausems MG
    Br J Cancer; 2014 Feb; 110(4):1081-7. PubMed ID: 24423928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial.
    Wevers MR; Ausems MG; Verhoef S; Bleiker EM; Hahn DE; Hogervorst FB; van der Luijt RB; Valdimarsdottir HB; van Hillegersberg R; Rutgers EJ; Aaronson NK
    BMC Cancer; 2011 Jan; 11():6. PubMed ID: 21219598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study.
    Wevers MR; Schmidt MK; Engelhardt EG; Verhoef S; Hooning MJ; Kriege M; Seynaeve C; Collée M; van Asperen CJ; Tollenaar RA; Koppert LB; Witkamp AJ; Rutgers EJ; Aaronson NK; Rookus MA; Ausems MG
    Fam Cancer; 2015 Sep; 14(3):355-63. PubMed ID: 25700605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients.
    Schwartz MD; Lerman C; Brogan B; Peshkin BN; Halbert CH; DeMarco T; Lawrence W; Main D; Finch C; Magnant C; Pennanen M; Tsangaris T; Willey S; Isaacs C
    J Clin Oncol; 2004 May; 22(10):1823-9. PubMed ID: 15067026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-reducing mastectomy in BRCA1/2 mutation carriers: factors influencing uptake and timing.
    van Driel CM; Eltahir Y; de Vries J; Jaspers JP; Oosterwijk JC; Mourits MJ; de Bock GH
    Maturitas; 2014 Feb; 77(2):180-4. PubMed ID: 24268650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer after bilateral risk-reducing mastectomy.
    Skytte AB; Crüger D; Gerster M; Laenkholm AV; Lang C; Brøndum-Nielsen K; Andersen MK; Sunde L; Kølvraa S; Gerdes AM
    Clin Genet; 2011 May; 79(5):431-7. PubMed ID: 21199491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
    Kiely BE; Jenkins MA; McKinley JM; Friedlander ML; Weideman P; Milne RL; McLachlan SA; Hopper JL; Phillips KA
    Breast Cancer Res Treat; 2010 Apr; 120(3):715-23. PubMed ID: 19669874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid genetic counseling and testing in newly diagnosed breast cancer: Patients' and health professionals' attitudes, experiences, and evaluation of effects on treatment decision making.
    Wevers MR; Aaronson NK; Bleiker EMA; Hahn DEE; Brouwer T; van Dalen T; Theunissen EB; van Ooijen B; de Roos MA; Borgstein PJ; Vrouenraets BC; Vriens E; Bouma WH; Rijna H; Vente JP; Kuenen MA; van der Sanden-Melis J; Witkamp AJ; Rutgers EJT; Verhoef S; Ausems MGEM
    J Surg Oncol; 2017 Dec; 116(8):1029-1039. PubMed ID: 28703900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy.
    Dettwyler SA; Thull DL; McAuliffe PF; Steiman JG; Johnson RR; Diego EJ; Mai PL
    Breast Cancer Res Treat; 2022 Jul; 194(2):393-401. PubMed ID: 35596825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk management options elected by women after testing positive for a BRCA mutation.
    Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
    Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).
    Lodder LN; Frets PG; Trijsburg RW; Meijers-Heijboer EJ; Klijn JG; Seynaeve C; van Geel AN; Tilanus MM; Bartels CC; Verhoog LC; Brekelmans CT; Burger CW; Niermeijer MF
    Breast Cancer Res Treat; 2002 May; 73(2):97-112. PubMed ID: 12088120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.
    Stolier AJ; Fuhrman GM; Mauterer L; Bolton JS; Superneau DW
    Breast J; 2004; 10(6):475-80. PubMed ID: 15569201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers.
    Laitman Y; Vaisman Y; Feldman D; Helpman L; Gitly M; Paluch Shimon S; Berger R; Cohen L; Narod SA; Friedman E
    Clin Genet; 2014 Jan; 85(1):68-71. PubMed ID: 23517234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1 and BRCA2 genetic test in high risk patients and families: counselling and management.
    Marchina E; Fontana MG; Speziani M; Salvi A; Ricca G; Di Lorenzo D; Gervasi M; Caimi L; Barlati S
    Oncol Rep; 2010 Dec; 24(6):1661-7. PubMed ID: 21042765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
    JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.